Single Strand Biotech is a biotechnology company leading the development of synthetic drugs based on single-stranded oligonucleotides (SSO), designed to modulate the immune system and promote tissue regeneration. We aim to offer next-generation therapies for treating chronic inflammatory diseases—starting with Crohn’s disease—through safe, effective, and long-lasting medications.

Founded by distinguished researchers and supported by an advisory board with extensive experience, SSBio combines academic excellence with a strong entrepreneurial spirit. With over two decades of research experience on SSO, the company has developed therapies that could redefine the traditional therapeutic approach. These therapies are based on the potential of certain single-stranded DNA molecules to restore immune system homeostasis and regenerate damaged tissues.